A prospective, multi-center, single-group target value method was used in this study. According to the inclusion criteria stipulated in this trial protocol, > 3 medical device clinical trial institutions with the record of the State Food and Drug Administration were selected as clinical centers, and 190 cases were selected (the first case of each center was taken as the imported case. Follow-up was carried out according to the program process, but the results were analyzed separately. Moderate-to-severe calcified stenosis patients who met all the inclusion criteria and did not meet any exclusion criteria were enrolled into the study. Lumen pretreatment was performed using the coronary shock catheter system and drug-eluting stents were implanted.

Subjects were followed up immediately after surgery, before discharge, 30±3 days after surgery, and 6 months ±14 days after surgery to evaluate the safety and effectiveness of coronary lithotripsy catheter system for preconditioning patients with moderate and severe coronary artery calcification stenosis.

In this study, the success rate of postoperative surgery was used as the primary endpoint, and major cardiovascular and cerebrovascular adverse events within 30 days after surgery were used as the secondary endpoint.

After the completion of the primary endpoint evaluation of the project, it shall be submitted together with other data to the competent department of medical device approval for initial registration. At the same time, continue to complete the follow-up of the subjects.

Inclusion Criteria:

1. Age ≥18 years old;
2. Subjects had primary coronary artery disease suitable for percutaneous coronary intervention (including stable or unstable angina pectoris and asymptomatic myocardial ischemia)
3. marker of myocardial injury： 3.1 For patients with unstable ischemic heart disease, the biomarker (CK-MB) must be within the normal range within 12 hours before surgery； 3.2 In patients with stable ischemic heart disease, biomarkers can be tested before or during surgery, and (CK-MB) must be within the normal range within 12 hours before or during surgery；
4. Patients were able to understand the content of the trial, volunteered to sign the informed consent, were willing to comply with the trial protocol, and had the ability to visit and check regularly;

Image inclusion criteria:

1. No stent has been implanted in the target lesion within 1 year, and no drug-eluting stent has been implanted within 5mm of the target lesion;

2. Single new stenosis of the left main artery of the target vessel, or of the anterior descending branch, right crown or circumflex branch (or its branches), with the following characteristics:

   1. Visual stenosis ≥70% and <100%; or
   2. Visual stenosis ≥50% but <70%, combined with evidence of clinical ischemia, such as typical clinical symptoms or positive tablet test results, or fractional flow reserve FFR≤0.80, or instantaneous waveform free ratio instantaneous wave-free ratio<0.90;

3. Moderate to severe calcification in the target lesion site is defined as:

   1. Angiography: Calcification can be detected in at least one location on either side of the arterial wall when the heart is beating or not under fluoroscopy before contrast medium injection; or
   2. Calcification ≥180° was present in at least one section by intravascular ultrasound.

4. The reference diameter of target vessels was between 2.5mm and 4.0mm;

5. Length of target lesion ≥5mm but ≤40mm;

6. Target vessels must have thrombolysis in myocardial infarction grade 3 before registration (can be evaluated after pre-dilation)

7. 0.014 inch guide wire can pass through the lesion;

Exclusion Criteria:

Basic condition (Cardiac function)

1. Left ventricular ejection fraction (LVEF) <40%;

2. New York Classification of Cardiac Function (NYHA) Class IV; Anatomical structure

3. There is a second lesion with an interval of more than 10mm and a stenosis degree of ≥50% in the same target vessel;

4. Target vessels were too circuitous, defined as the presence of two or more bends >90º or three or more bends >75º;

5. Definite or probable thrombus in the target vessel;

6. Evidence of aneurysm in the target vessel within 10mm of the target lesion;

7. The target lesion is located in the primary vessel that can only be reached by saphenous vein or arterial graft bypass;

8. There were restriction-limiting dissection with NHLBI (National Heart, Lung, and Blood Institute)grade ≥D in the target vessels before registration.

9. Chronic occlusive disease (CTO) : CTO exists in other main vessels outside the target vessel (anterior descending branch, circumflex branch, right crown) or CTO exists in any location of the target vessel.

10. Target lesions need to be pretreated with special balloons such as rotary grinding and spinous process balloon; Laboratory tests

11. uncontrolled severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure > 120 mmHg);

12. Acute myocardial infarction (MI) within the past 1 month, and/or signs of active myocardial ischemia at enrollment, including elevated troponin-I or T (with elevated CK), ischemic ECG changes, or chest pain;

13. Severe impairment of liver and kidney function, aminotransferase more than 3 times the upper limit of normal, creatinine > 2.5 mg/dL (221 μmol/L) or chronic renal failure requiring long-term dialysis; Note: In subjects with proven or suspected acute MI (as determined by the primary and secondary investigators), markers of myocardial injury must be evaluated prior to enrollment.

    Medical history and Others

14. 14. History of stroke or transient ischemic attack (TIA) within 30 days;

15. Patients with active peptic ulcer or upper gastrointestinal bleeding within 30 days;

16. Had undergone percutaneous coronary intervention within 14 days;

17. Patients who were scheduled to undergo a cardiovascular intervention within 30 days after this procedure;

18. Patients refuse or are not candidates for emergency coronary artery bypass grafting (CABG) surgery;

19. Drug-eluting stents have been implanted in target vessels within the past year;

20. Patients with known allergies or contraindications to the raw materials or drugs of the test products (such as antiplatelet drugs, anticoagulants, contrast agents);

21. Participating in other clinical trials;

22. The patient's expected survival was less than 1 year;

23. Women planning to have children during pregnancy, breastfeeding or clinical trials;

24. Factors that other researchers believe cannot be included